US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.52 against a street estimate of -0.04 — a beat of 1400.0%.
Analysts rate Alkermes Plc a buy (9 buy, 6 hold, 0 sell out of 15) with an average price target of $56.00.
CONFIDENT Alkermes delivered strong Q2 results with 34% YoY proprietary product growth, expanded sleep/narcolepsy leadership via LUMRYZ integration and alixorexton Phase 3 progress, and initiated ADHD/fatigue orexin programs. CEO transition to Blair Jackson next week. Q2 2026 No geographic segments disclosed. Analysts probed orexin multi-indication strategy (ADHD pediatric translatability, fatigue endpoints, combo therapy) and competitive positioning vs. Takeda/Lilly. Management emphasized early clinical data (Phase 1b/2a), FDA alignment on endpoints, and post-approval combo exploration rather than registration combos. Tone: confident but measured on timeline and regulatory certainty. 2026-07-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.88% |
| Baker Bros Advisors LP | 5.97% |
| Vanguard Portfolio Management, LLC | 5.67% |
| State Street Corp | 5.64% |
| Vanguard Capital Management, LLC | 4.43% |
| Renaissance Technologies Corp | 3.67% |
| T. Rowe Price Associates, Inc. | 2.78% |
| COMMODORE CAPITAL LP | 2.50% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 ALKERMES PLC - 8-K SUMMARY (SEPTEMBER 2026) HEADLINE NUMBERS • Board size increased from 10 to 11 directors on September 14, 2026 • New director equ | 2026-09-16 |
| Material agreement · Q3 2026 ALKERMES PLC (ALKS) - 8-K SUMMARY HEADLINE NUMBERS • Term Loan A (TLA) outstanding principal: $745,312,500 • Term Loan B (TLB) outstanding principal | 2026-08-12 |
| Quarterly report · Q2 2026 ALKERMES PLC — FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Total revenues (6 months): $888.9 million (vs. $697.2 milli | 2026-07-28 |
| Results announced · Q3 2026 ALKERMES PLC Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenues: $496.0 million (vs. $390.7 million in Q2 2025, +27% YoY) • | 2026-07-28 |
| Current report · Q3 2026 ALKERMES PLC - 8-K SUMMARY (July 6, 2026) HEADLINE NUMBERS • Agreement terminated: Authorized Generic Product Supply Agreement with Amneal Pharmaceu | 2026-07-08 |
| Reg FD disclosure · Q2 2026 ALKERMES PLC - 8-K FILING SUMMARY Date of Report: June 15, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Alkermes plc announced that the U.S. Food and D | 2026-06-15 |
| Quarterly report · Q1 2026 ALKERMES PLC – Q1 2026 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue (Q1 2026): $392.9 million, up 28% from $306.5 million in Q1 2025 | 2026-05-05 |
| Proxy statement · Q2 2026 ALKERMES PLC PROXY STATEMENT SUMMARY CEO COMPENSATION & CHANGE • Richard F. Pops (CEO and Chairman) total compensation for 2025: exact figure not di | 2026-04-06 |
Readable in the app.
| Announcement | Date |
|---|---|
| Acquisition of Avadel Pharmaceuticals completed in February 2026 Alkermes plc reported strong Q1 2026 results with total revenues of $392.9 million, up 28% from $306.5 million in Q1 2025. The company completed its acquisition of Avadel Pharmaceuticals in | 2026-05-05 |
| Completion of Avadel acquisition strengthens leadership position in sleep medicine Alkermes plc reported 2025 financial results showing total revenues of $1.48 billion with net income of $242 million ($1.43 diluted EPS). Proprietary product sales grew approximately 9% year | 2026-02-25 |
| Completed acquisition of Avadel Pharmaceuticals plc for wholly owned subsidiary On February 12, 2026, Alkermes completed its acquisition of Avadel Pharmaceuticals for $21.00 per share in cash, plus contingent value rights (CVRs) worth up to an additional $1.50 per share | 2026-02-12 |
| Planned acquisition of Avadel Pharmaceuticals announced Alkermes, a neuroscience pharmaceutical company, announced a strong 2025 with commercial revenues of $1.45 billion, solid cash flow, and profitability. The company is executing on multiple g | 2026-01-12 |
| Amendment to acquisition agreement and revised offer announcement Alkermes plc announced updates to its planned acquisition of Avadel Pharmaceuticals plc on November 18-19, 2025. The company amended the original transaction agreement and secured a bridge t | 2025-11-19 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alkermes Plc — free to start.
Google PlayApp StoreData updated 2026-09-18.